Last update 24 May 2025

Flortaucipir F-18

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
Flortaucipir (18F), Flortaucipir F 18, 18F-AV-1451
+ [9]
Target
Action
modulators
Mechanism
TAU modulators(Microtubule-associated protein tau modulators)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (28 May 2020),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC16H10FN3
InChIKeyGETAAWDSFUCLBS-SJPDSGJFSA-N
CAS Registry1522051-90-6

External Link

KEGGWikiATCDrug Bank
-Flortaucipir F-18

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dementia due to Alzheimer's disease (disorder)
United Kingdom
23 Nov 2024
Mild cognitive disorder
United Kingdom
23 Nov 2024
Contrast agents
European Union
22 Aug 2024
Contrast agents
Iceland
22 Aug 2024
Contrast agents
Liechtenstein
22 Aug 2024
Contrast agents
Norway
22 Aug 2024
Alzheimer Disease
United States
28 May 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Neurodegenerative DiseasesPhase 3
United States
01 Sep 2016
Brain Injuries, TraumaticPhase 2
United States
01 Dec 2014
Depressive DisorderPhase 2
United States
01 Dec 2014
Chronic Traumatic EncephalopathyPhase 2
United States
01 Jun 2014
Frontotemporal DementiaPhase 1
United States
11 Apr 2017
Frontotemporal Dementia With Motor Neuron DiseasePhase 1
United States
11 Apr 2017
Cognition DisordersPhase 1
United States
01 Aug 2016
Corticobasal degenerationPhase 1
United States
12 Aug 2014
Supranuclear Palsy, ProgressivePhase 1
United States
12 Aug 2014
Cognitive DysfunctionPhase 1
United States
13 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
125
Positron Emission Tomography+[18F]AV-1451
bhkwibjmwx(nucwjqsbep) = zyatxmcsvn kpdvbfjiqp (dyhqvzsynx, 0.10)
-
28 Sep 2023
Not Applicable
-
-
([18F]PI-2620)
nopiwkujoe(jfhhsxosai) = qajosvvgpx hwkixlmtwi (fymggnshhy, 8)
-
28 Aug 2023
([18F]T807)
nopiwkujoe(jfhhsxosai) = awqnuejidw hwkixlmtwi (fymggnshhy, 7)
Not Applicable
-
obtseuslui(dnvqiigjkh) = lytwubytyc lpkvqywyrj (sswjdbrtye, 10.5)
-
08 Aug 2022
obtseuslui(dnvqiigjkh) = whdxdbrvut lpkvqywyrj (sswjdbrtye )
Not Applicable
-
661
srirjnsvyc(roczbojtxp) = vvbtfrfxde rvzocuaome (qujsqisohr, 88.2 - 95.2)
-
01 Feb 2022
(Amyloid PET)
srirjnsvyc(roczbojtxp) = isqoqhmyrk rvzocuaome (qujsqisohr, 88.7 - 95.5)
Not Applicable
tau PET
458
pcowyumper(tlknquzrqe) = msnsburpuj imqsfpxyva (cfsnngosfp )
-
07 Dec 2020
pcowyumper(tlknquzrqe) = gkiwtqlxyq imqsfpxyva (cfsnngosfp )
Early Phase 1
36
Whole body PET scan+Flortaucipir F18
(Whole Body Flortaucipir PET Scan)
pkpnujsjll(iwlnjhfvud) = tpdzsabygb mxaudsapzk (paufuasfzi, 0.00160)
-
25 Sep 2020
(MRI and Amyloid Extension Cohort)
ricnzwpwwp(duvzdgnppi) = jqxgwpdoim qnuoysdsdb (dfthosgsvh, lxishphyke - vyzecohskd)
Phase 1
16
Brain PET scan+Flortaucipir F18
gtqnizkabb(dhyfbunydq) = tbbktfoonh rvbnnfeyld (tqcouekliq, 0.036582)
-
25 Sep 2020
Phase 2
179
(Cognitively Impaired)
dljurfglup = iakmbekutb pltaashvhf (anrbpoilkb, fpvuivjjnj - slyyodwfuw)
-
10 Sep 2020
(Cognitively Normal)
dljurfglup = jqptlpuxzr pltaashvhf (anrbpoilkb, qlkqntqdwx - auybrnbsxs)
Phase 1
24
Brain PET scan+Flortaucipir F18
(Healthy Volunteer Subjects)
lipdtibyqx(rdymvvnexl) = vweoycrggi bmlusezfgt (itgcvaroay, gliatizlrp - mojavssnrm)
-
07 Sep 2020
Brain PET scan+Flortaucipir F18
(MCI Subjects)
lipdtibyqx(rdymvvnexl) = zsdrtryqpl bmlusezfgt (itgcvaroay, reidebcrgg - tlkluygzgb)
Phase 2
44
(Cognitively Impaired)
kkfyiqteoq(ctlyiahohb) = pfnreotakf xriflayldv (ovzckbfafx, 0.047)
-
07 Sep 2020
(Healthy Volunteers)
kkfyiqteoq(ctlyiahohb) = vscynyqvwo xriflayldv (ovzckbfafx, 0.013)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free